Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3)
Kristian Reich(Dermatologikum Hamburg), Howard Sofen(VA Sepulveda Ambulatory Care Center), Yukari Okubo(Tokyo Medical University), Mark Lebwohl(Mount Sinai Hospital), Francisco A. Kerdel(Florida Academic Dermatology Center), Orin M. Goldblum(Eli Lilly (United States)), Ricardo Romiti(Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo), Ellen B. Dennehy(Purdue University West Lafayette), Lisa Kerr(Eli Lilly (United States)), Craig L. Leonardi(Central Dermatology)
Cited by 56
Related Papers
The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation
|Psychological Medicine|2004|989
Effectiveness of Adjunctive Antidepressant Treatment for Bipolar Depression
|New England Journal of Medicine|2007|925
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics
|Journal of the American Academy of Dermatology|2019|917
Psoriasis
|Nature Reviews Disease Primers|2016|893